REG - Societe Generale SA Takeda Pharma.Co.Ltd - Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD

Takeda Pharmaceutical CoAnnouncement

13/11/2018 08:35

RNS Number : 1719H
Societe Generale SA
13 November 2018
 


FORM 8.3
 
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the "Code")
 
1.         KEY INFORMATION     
 



(a) Full name of discloser:


Société Générale S.A.




(b) Owner or controller of interests and short positions disclosed, if different from 1(a):
     The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.


 
 
 




(c) Name of offeror/offeree in relation to whose relevant securities this form relates:
     Use a separate form for each offeror/offeree


Takeda Pharmaceutical CO LTD




(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:








(e) Date position held/dealing undertaken:
     For an opening position disclosure, state the latest practicable date prior to the disclosure


12/11/2018       




(f)  In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
     If it is a cash offer or possible cash offer, state "N/A"


YES: Shire PLC
 



 
2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE
 
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
 
(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
 



Class of relevant security:
 


Ordinary




 
 


Interests


Short positions








Number


%


Number


%




(1) Relevant securities owned and/or controlled:


2,037,019


0.26


7,722,607


0.98




(2) Cash-settled derivatives:
 


6,889,533


0.88


2,061


0.00




(3) Stock-settled derivatives (including options) and agreements to purchase/sell:


121,500


0.02


125,000


0.02




 
     TOTAL:


9,048,052


1.15


7,849,668


1.00



           
All interests and all short positions should be disclosed.
 
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
 
(b)        Rights to subscribe for new securities (including directors' and other employee options)
 



Class of relevant security in relation to which subscription right exists:








Details, including nature of the rights concerned and relevant percentages:







 
3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
 
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
 
The currency of all prices and other monetary amounts should be stated.
 
(a)        Purchases and sales



Class of relevant security


Purchase/sale


Number of securities


Price per unit
JPY




Ordinary


Purchase


200


4508




Ordinary


Purchase


400


4506




Ordinary


Purchase


400


4519




Ordinary


Purchase


1,500


4508




Ordinary


Purchase


1,400


4483




Ordinary


Purchase


1,500


4499




Ordinary


Purchase


100


4504




Ordinary


Purchase


400


4530




Ordinary


Purchase


300


4525




Ordinary


Purchase


300


4503




Ordinary


Purchase


1,700


4494




Ordinary


Purchase


1,500


4515




Ordinary


Purchase


2,400


4524




Ordinary


Purchase


100


4509




Ordinary


Purchase


1,400


4502




Ordinary


Purchase


1,200


4507




Ordinary


Purchase


1,500


4508




Ordinary


Purchase


800


4508




Ordinary


Purchase


100


4507




Ordinary


Purchase


100


4516




Ordinary


Purchase


100


4511




Ordinary


Purchase


100


4508




Ordinary


Purchase


1,400


4508




Ordinary


Purchase


2,100


4538




Ordinary


Purchase


1,100


4503




Ordinary


Purchase


300


4510




Ordinary


Purchase


100


4516




Ordinary


Purchase


700


4548




Ordinary


Purchase


200


4549




Ordinary


Purchase


1,000


4546




Ordinary


Purchase


500


4505




Ordinary


Purchase


600


4510




Ordinary


Purchase


700


4511




Ordinary


Purchase


1,000


4550




Ordinary


Purchase


800


4507




Ordinary


Purchase


100


4500




Ordinary


Purchase


1,200


4501




Ordinary


Purchase


400


4501




Ordinary


Purchase


100


4506




Ordinary


Purchase


200


4507




Ordinary


Purchase


200


4505




Ordinary


Purchase


300


4508




Ordinary


Purchase


1,000


4509




Ordinary


Purchase


1,000


4513




Ordinary


Purchase


100


4501




Ordinary


Purchase


400


4500




Ordinary


Purchase


600


4569




Ordinary


Purchase


1,100


4507




Ordinary


Purchase


1,000


4511




Ordinary


Purchase


1,000


4540




Ordinary


Purchase


1,100


4506




Ordinary


Purchase


1,000


4557




Ordinary


Purchase


3,500


4559




Ordinary


Purchase


200


4534




Ordinary


Purchase


100


4503




Ordinary


Sale


1,400


4559




Ordinary


Sale


100


4548




Ordinary


Sale


100


4531




Ordinary


Sale


100


4540




Ordinary


Sale


100


4496




Ordinary


Sale


100


4549




Ordinary


Sale


3,700


4559




Ordinary


Sale


300


4508.5




Ordinary


Sale


400


4540.5




Ordinary


Sale


100


4530.5




Ordinary


Sale


400


4530.5




Ordinary


Sale


300


4549




Ordinary


Sale


100


4549




Ordinary


Sale


500


4499




Ordinary


Sale


400


4512.5




Ordinary


Sale


400


4502.5




Ordinary


Sale


600


4502.5




Ordinary


Sale


300


4510.5




Ordinary


Sale


600


4506.5




Ordinary


Sale


500


4514




Ordinary


Sale


300


4509.5




Ordinary


Sale


400


4498.5




Ordinary


Sale


500


4497




Ordinary


Sale


400


4507.5




Ordinary


Sale


300


4507




Ordinary


Sale


400


4504.5




Ordinary


Sale


500


4508.5




Ordinary


Sale


100


4518.5




Ordinary


Sale


500


4538




Ordinary


Sale


600


4510




Ordinary


Sale


100


4518




Ordinary


Sale


2,800


4484




Ordinary


Sale


500


4523




Ordinary


Sale


100


4519




Ordinary


Sale


1,200


4518




Ordinary


Sale


600


4503




Ordinary


Sale


100


4521




Ordinary


Sale


1,300


4535




Ordinary


Sale


2,200


4550




Ordinary


Sale


200


4510




Ordinary


Sale


400


4519




Ordinary


Sale


100


4503




Ordinary


Sale


500


4505




Ordinary


Sale


800


4500




Ordinary


Sale


1,000


4539




Ordinary


Sale


700


4491




Ordinary


Sale


700


4502




Ordinary


Sale


1,000


4513




Ordinary


Sale


1,000


4513




Ordinary


Sale


700


4514




Ordinary


Sale


300


4516




Ordinary


Sale


100


4517




Ordinary


Sale


600


4506




Ordinary


Sale


100


4506




Ordinary


Sale


1,000


4501




Ordinary


Sale


2,400


4559




Ordinary


Sale


300


4535




Ordinary


Sale


300


4517




Ordinary


Sale


300


4505








Total Purchases


42,600












Total Sales


35,900







 
 
(b)        Cash-settled derivative transactions
 



Class of relevant security


Product description
e.g. CFD


Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position


Number of reference securities


Price per unit JPY

























 
 (c)       Stock-settled derivative transactions (including options)
 
(i)         Writing, selling, purchasing or varying
 



Class of relevant security


Product description e.g. call option


Writing, purchasing, selling, varying etc.


Number of securities to which option relates


Exercise price per unit


Type
e.g. American, European etc.


Expiry date


Option money paid/ received per unit JPY





































 
(ii)        Exercise
 



Class of relevant security


Product description
e.g. call option


Exercising/ exercised against


Number of securities


Exercise price per unit JPY




















 
 



 
(d)        Other dealings (including subscribing for new securities)
 



Class of relevant security


Nature of dealing
e.g. subscription, conversion


Details


Price per unit (if applicable) JPY








 
 











4.         OTHER INFORMATION
 
(a)        Indemnity and other dealing arrangements
 



Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"




 
 
 



 
(b)        Agreements, arrangements or understandings relating to options or derivatives
 



Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i)  the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"




 
 
 



 
(c)        Attachments
 



Is a Supplemental Form 8 (Open Positions) attached?


YES



 
 



Date of disclosure:


13/11/2018




Contact name:


Olivier Vero




Telephone number:


+44 20 7676 6969



 
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
 
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk           




SUPPLEMENTAL FORM 8 (OPEN POSITIONS)
 
DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.
Note 5(i) on Rule 8 of the Takeover Code (the "Code")
 
 
1.         KEY INFORMATION
 



Full name of person making disclosure:


SOCIETE GENERALE SA




Name of offeror/offeree in relation to whose relevant securities the disclosure relates:


Takeda Pharmaceutical CO LTD



 
2.         STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
 
 



Class of relevant security


Product description e.g. call option


Written or purchased


Number of securities to which option or derivative relates


Exercise price per unit


Type


Expiry date




JPY


e.g. American, European etc.




Ordinary


OTC put-option


Sale


15,700


4707


European options


14/12/2018




Ordinary


OTC put-option


Sale


30,000


5075.10


European options


14/12/2018




Ordinary


OTC put-option


Sale


29,600


5073.65


European options


14/12/2018




Ordinary


OTC put-option


Sale


15,500


4491.40


European options


14/12/2018




Ordinary


OTC put-option


Sale


30,700


4533.90


European options


14/12/2018




Ordinary


Listed call-option


Sale


125,000


5500


European options


13/06/2019



 
 
 
3.         AGREEMENTS TO PURCHASE OR SELL ETC.
 



Full details should be given so that the nature of the interest or position can be fully understood:




 
 
 
 
 



 
It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.
 
The currency of all prices and other monetary amounts should be stated.
 
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
 
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RETGGGUWGUPRURW